Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Dravet syndrome
Biotech
Stoke's shares up 90% as epilepsy drug cuts convulsive seizures
Investors are stocking up on Stoke, sending the biotech’s shares flying 90% premarket on the back of positive phase 1/2a data for a seizure medicine.
Annalee Armstrong
,
James Waldron
Mar 26, 2024 9:09am
Longboard’s shares triple as epilepsy med halves seizure rates
Jan 2, 2024 10:49am
Ovid sells some royalty rights to Takeda-partnered seizure drug
Oct 18, 2023 8:00am
Stoke shares drop 30% as Dravet drug posts high adverse events
Jul 25, 2023 11:49am
Encoded lays off 10% of staff after back-to-back $100M+ rounds
Jun 13, 2023 3:25pm
PsychoGenics on board for Iama's Dravet syndrome study
Jan 19, 2023 4:30am